Giant Biogene Holding Co., Ltd.

HKSE 2367.HK

Giant Biogene Holding Co., Ltd. EBIT Margin for the year ending December 31, 2023: 49.52%

Giant Biogene Holding Co., Ltd. EBIT Margin is 49.52% for the year ending December 31, 2023, a -0.58% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Giant Biogene Holding Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 49.81%, a -15.44% change year over year.
  • Giant Biogene Holding Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 58.91%, a 7.59% change year over year.
  • Giant Biogene Holding Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 54.75%, a -23.94% change year over year.
  • Giant Biogene Holding Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 71.98%.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
SV Wall Street
HKSE: 2367.HK

Giant Biogene Holding Co., Ltd.

CEO Mr. Jianya Yan
IPO Date Nov. 4, 2022
Location China
Headquarters No. 1855, Shanglin Yuan
Employees 1,512
Sector Consumers Staples
Industries
Personal Care Biotechnology Cosmetics Dental Care Eyewear Luxury Goods Pharmaceuticals Plastics
Description

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

StockViz Staff

February 8, 2025

Any question? Send us an email